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Sarcopenia, the progressive loss of muscle mass and strength, is one of the major
health issues in older adults, given its high prevalence accompanied by huge clinical and
socioeconomic implications. Age-related changes in skeletal muscle can be attributed to
mechanisms both directly and indirectly related to muscle homeostasis. Indeed, a wide
spectrum of age-related modifications in the organism was shown to play a key role in the
pathogenesis of sarcopenia. Not surprisingly, sarcopenia has sometimes been indicated
as a syndrome stemming from the aging process, and not as univocal standalone
disease. Due to the multidimensionality of sarcopenia, a single biomarker approach is
not enough to explain the biology of this condition. The aim of this review is to suggest
innovative and promising sarcopenia markers investigating the link between skeletal
muscle and brain. Indeed, as a neurological origin of sarcopenia has been hypothesized,
a new perspective on sarcopenia biomarkers may focus on the dysfunction of the
neuromuscular junctions (NMJs). The core SNARE synaptosomal-associated protein of
25 kDa (SNAP25) accumulates in the plasma membrane of nerve terminals at NMJs
and regulates exocytosis at peripheral and central synapses. Interestingly, mice studies
have shown that SNAP25 affects the neuromuscular function. SNARE complex and,
in particular, SNAP25 may represent a promising pathway to explore the molecular
and cellular mechanisms regulating muscular homeostasis and concur at profiling the
sarcopenia biological background.
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AGING AND SARCOPENIA
The global increase of human life expectancy and the rapid aging of the population represent
emerging major sociodemographic phenomena.
The aging phenotype is heterogeneous and individuals of the same chronological age may
dramatically differ in their health status from each other. In this context, over the past decades,
the concept of frailty has been used to define age-related condition characterized by increased
vulnerability of physiological systems to stressors, exposing individuals to increased risk of negative
outcomes (1).
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The physical manifestation of frailty is typically described as
dominated by the presence of sarcopenia, one of the most notable
changes in body composition being defined by the loss of skeletal
muscle mass and strength (2).
The prevalence of sarcopenia in persons aged 60–70 years old
is reported to be between 5 and 13%, but it increases to 11–
50% in people older than 80. Starting since the age of 40 years,
individuals lose 1–2% of muscle per year. At the age of 70 years,
25–30% of skeletal muscle mass is lost, and muscle strength even
more pronouncedly is declined by up to 40% (3).
In older persons, the etiology of sarcopenia is multi-factorial.
Under normal circumstances, physiologic muscle mass and
function are related to a dynamic balance between positive
and negative regulators of muscle growth. The central nervous,
immune, and endocrine systems coordinate this balance. The
sarcopenia onset and progression depend on a combination
of mechanisms, typically involved in the aging process, whose
combination results in the disruption of the normal physiology
of skeletal muscle (4).
Among the age-related changes in body composition
occurring at the level of the muscle fiber structure, modifications
of its contractile properties and abnormalities of neuromuscular
junctions (NMJs) are particularly evident. In particular,
sarcopenia shows a muscle fiber distribution with a
predominance of type I fibers correlated to an atrophy of
type II fibers (5), and an accumulation of adipose tissue both
around and between muscle fibers (6). Notably an altered protein
metabolism and a dysregulated autophagy leading to muscle
atrophy play a role as well in this phenomenon. The picture
is even more complex because mechanisms indirectly related
to muscle homeostasis also participate in the pathogenesis of
sarcopenia (i.e., hormonal status, inflammatory status, insulin
resistance, telomere shorting, and oxidative stress).
More recently, a neurological origin of sarcopenia has been
postulated (7). Since the integrity of the neurophysiological
functions plays a pivotal role for the maintenance of the skeletal
muscle in older persons (8), it has been hypothesized that a brain-
muscle link could underlie of the sarcopenia development. The
assumption that the muscle contractile activity is regulated by
the central nervous system (CNS) at the NMJs suggests that the
functionality of the NMJs is indispensable for the maintenance
of both motor nerve and muscle fibers (9). NMJs have the
characteristic structural features of chemical synapses acting as
interface between nervous and skeletal muscular system. Age-
related alterations in the nervous system play pivotal a role in
the musculoskeletal impairment and the decline of the muscle
power generation (10). Such age-related remodeling includes loss
of motor neurons and transformations of motor units through
collateral reinnervation (11), impairment of neuromuscular
activation (12), and uncoordinated patterns of intermuscular
neural activation (13).
Under these premises, it is evident that sarcopenia is
characterized by a peculiar multidimensionality and a
consequent heterogeneity. For this reason, the “one-fits-
all” approach, where a single process is able to explain the
clinical manifestation, may be inadequate for capturing the inner
biological foundations of this condition. Thus, a single biomarker
is not enough to explain the biology of this complex age-related
condition and cannot distinguish sarcopenia from a mere
condition of advanced age. Only considering a multidimensional
strategy to discover biomarkers of sarcopenia it will be possible
to isolate the real fingerprints of this disease.
This review aims to summarize the available literature on
sarcopenia biomarkers and to propose innovative and promising
ones. Under this perspective, we extended the investigation
of the non-muscle-specific sarcopenia biomarkers deepening
the analysis of the molecular pathway related to the brain-
muscle link.
BIOMARKERS OF SARCOPENIA
In recent years, many studies on sarcopenia have identified
numerous biochemical biomarkers. These biomarkers could be
divided in “muscle-specific” and “non-muscle-specific.”
Established Biomarker of Sarcopenia
Muscle-Specific Biomarkers
The muscle-specific biomarkers should ideally be able to evaluate
both muscle mass and strength loss, the two dimensions
of sarcopenia.
Several techniques are used to quantify muscle mass.
The measurement of muscle or fat free mass is usually
obtained by using imaging assessments as the dual energy
X-ray absorptiometry, the computerized tomography, the
magnetic resonance imaging, or bioelectrical impedance analysis.
However, the current lack of a univocal operational definition
and the absence of a clear “gold standard” assessment method
make the diagnostic problem still problematic.
Multiple tests of physical performance are available, including
the gait speed, the Short Physical Performance Battery (SPPB),
the 6-min walk test, and the stair climb power test. Unfortunately,
each of them has own characteristics and only captures
specific aspects of the muscle functioning, thus concurring
at the heterogeneous set of possibilities in the measurement
of sarcopenia.
In the last years, a number of muscle-specific biomarkers
of sarcopenia have been identified. Recently, several studies
have raised doubts about the specificity of these markers in
detecting sarcopenia.
Among the “muscle-specific” biochemical markers there are
several linked to muscle turnover. Procollagen type III N-
terminal peptide (P3NP) is a fragment released by the proteolytic
cleavage during collagen synthesis in the muscle. It represents an
interesting marker for the analysis of skeletal muscle remodeling.
Evidence shows that serum P3NP concentrations reflect the
muscle mass (14). However, P3NP levels are altered also
in autoimmune diseases as psoriasis, psoriatric arthritis, and
rheumatoid arthritis (15).
The peptides deriving from the collagen type VI turnover, as a
type VI collagen N-terminal globular domain epitope (IC6) and
MMP-generated degradation fragment of collagen 6 (C6M) could
be potential markers for the muscle loss.
Collagen type VI has been proposed as a biomarker of
muscular tissue damage (16). This protein is important for
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the preservation of muscle trophism; in fact, genetic defects
of this protein are linked to very serious muscular diseases.
Nevertheless, these molecules were found to be altered also in
serum of cancer patients (17).
The 3-methylhistidine (3MH) results from the methylation of
histidine residues of actin and myosin, and induces proteolysis
of myofibrils; evidence showed that it could be implicated in
the sarcopenia pathophysiology (18). It must be taken into
consideration that 3MH is strongly influenced by dietary habits
and meat consumption (19).
Skeletal muscle-specific isoform of troponin T (sTnT) may be
considerate a biomarker of sarcopenia, since high troponin levels
are an expression of muscle wasting. Abreu et al. (20) showed that
serum levels of cardiac troponin T (cTnT) decrease in relation to
a physical performance improvement, opening new hypotheses
about this molecule as marker of muscle damage. It is well-
known that cTnT is a biomarker of cardiac dysfunctions as well
as diabetes, pulmonary arterial hypertension, and chronic kidney
disease (21).
The fact that creatine is related to the skeletal muscle state
should also not underestimated. Urinary creatine excretion is
correlated with the skeletal muscle mass of total body, and
increasing evidences demonstrate that creatine supplementation
results in positive effects on muscle strength (22). However,
urinary creatine excretion is also altered in other organism
dysfunctions as testicular damage (23).
Non-muscle-specific Biomarkers
A lot of non-muscle-specific biomarkers were found to be
related to sarcopenia pathology. However, these markers are also
involved in mechanisms underlying the aging process and could
be modified by environmental factors as lifestyle, comorbidity,
diseases, and exposure to drugs. In particular:
i) Markers of inflammatory system. An imbalance between
pro- and anti-inflammatory pathways, responsible for
a smoldering low-grade inflammation (the so-called
“inflamm-aging” phenomenon) characterizes aging (24).
In this situation increased levels of pro-inflammatory
cytokines and reduced serum level of anti-inflammatory
cytokines are observed. Inflamm-aging could contribute
to sarcopenia exerting pro-sarcopenic effects through the
inhibition of muscle regeneration (25). Indeed, in older
adults, up-regulated levels of C-reactive protein, interleukin-
6, interleukin-8, tumor necrosis factor-α, interferon-γ,
granulocyte-monocyte colony-stimulating factor, and high-
temperature requirement serine protease A1 are related to
muscle mass, strength and physical function impairment
(26). Moreover, high circulating extracellular heat shock
protein 72, a mediator of inflammatory system, results in
low muscle mass, weak grip strength, and slow walking
speed (27).
ii) Markers of oxidative damage. Oxidative stress and the
accumulation of reactive oxygen species increase with aging,
and are likely to play an active role in triggering sarcopenia.
If free radicals are not eliminated by the anti-oxidant agents,
they cause severe damage on muscle cells. Evidence shows
that serum concentrations of protein carbonyls, well-known
markers of oxidative stress, are related with grip strength.
Advanced glycation end products (AGEs) are bioactive
compounds formed by non-enzymatic glycation of DNA,
proteins, and lipids. Elevated serum levels of AGEs are
linked to muscle strength impairment (28), however altered
expression of AGEs is related also to diabetes (29).
iii) Markers of nutritional status. In older persons the physical
performance impairment is associated to anemia with low
hemoglobin or low serum albumin and/or selenium (30).
Leptin seems to affect the skeletal muscle, through the
modulation of lipolysis and insulin sensitivity. Considering
that the muscle is the major user of glucose, sarcopenia may
represent a risk factor for the development of insulin resistance
(31). Evidences showed an increase of circulating levels of
leptin in sarcopenia due to a reduction of leptin receptors
along with a loss of muscle mass.
In elder people, positive relationships between plasma
levels of uric acid and handgrip (32) and between magnesium
levels and indexes of muscle performance were observed (33).
Moreover, the skeletal muscle health is linked to vitamin
D. Vitamin D affects muscle cell contractility, proliferation,
and differentiation (34). Vitamin D insufficiency results in
muscle deficits and vitamin D supplementation has beneficial
effects. Further, the identification of vitamin D receptor in
skeletal muscle provides evidence for its direct effect on
sarcopenia (35).
iv) Markers of endocrine system. Loss of muscle mass is also
caused by the reduced capacity for synthesizing proteins
and repairing muscle damage which implies a progressive
switch from anabolic to catabolic metabolism. It was
found that defects in muscle protein homeostasis might
be associated to changes in circulating levels of hormones.
Studies showed that sex hormones, including testosterone
and dehydroepiandrosterone sulfate (DHEAS), whose levels
decrease during age, have a role in the sarcopenia onset
(36). Testosterone has an anabolic, anti-catabolic, and anti-
inflammatory effect on muscle, stimulating cell activation,
proliferation, survival, and differentiation, thus playing a role
in maintenance of muscle homeostasis (37). DHEAS may
affect muscle performance and its age-associated decline is an
important determinant of muscle mass and strength loss in
older people (38). Sarcopenia is characterized also by a decline
of the growth hormone (GH) and the insulin-like growth
factor 1 (IGF-1). The actions of GH are mediated by IGF-1,
an anabolic hormone, which stimulates muscle growth and
regeneration. Giovannini et al. (39) demostrated that IGF-1
administration increases the rate of skeletal muscle functional
recovery after injury.
v) Markers related to growth factors. Myostatin and the
growth differentiation factor-15 (GDF-15), members of
the transforming growth factor-β (TGF-β) superfamily,
are negative regulators of skeletal muscle myogenesis and
inhibitors of muscle growth. Interestingly, it was found
that older myostatin-null mice show resistance to the
sarcopenic phenotype (40) and the use of antibodies
against myostatin lead to an improvement of muscle mass
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and grip strength (41). Follistatin, a myostatin inhibitor,
seems to be an interesting tool in evaluating the muscle
damage (42). Another sarcopenia biomarker is brain-
derived neurotrophic factor (BDNF), which induces the
production of growth factors associated with differentiation,
plasticity, and neuronal growth. In skeletal muscle, BDNF
is involved in the regulation and survival of motoneurons,
in the development and differentiation of myoblasts, in the
interaction between immune cells and muscle cells (43).
However, myostatin and follistatin are altered in osteoarthritis
(44, 45), GDF-15 in cardiovascular disease (46), and BDNF
in mood disorders (47) and deregulated heart autonomic
system (48).
vi) Markers of NMJ dysfunction. In the skeletal muscle,
NMJs are implicated in the transduction of the action
potentials, and their dysfunction can lead to a gradual
alteration of this process. The structural features of NMJs
are similar to chemical synapses and many molecules
involved in the formation of the NMJs have an essential
role in their maintenance (49). Agrin is a heparan sulfate
proteoglycan synthesized at the levels of motor neurons,
transported along axons and released into the synaptic
basal lamina of the NMJs. Here agrin stimulates the
assembly of the postsynaptic apparatus, including the
clustering of acetylcholine receptors and the stabilization
of presynaptic structures. Agrin is fundamental for the
formation and stabilization of NMJs (50). The proteolytic
cleavage of agrin at the NMJs by neurotrypsin produces a C-
terminal 22-kDa fragment (CAF), which is released into the
circulation and can be detected in human serum. Elevated
serum CAF levels resulting from NMJs disassembly and
denervation are associated with sarcopenia (51) and kidney
dysfunction (52).
Promising Biomarker of Sarcopenia
Core SNARE Synaptosomal-Associated Protein of 25
kDa (SNAP25)
Under these premises, a single biomarker approach is not enough
to explain the real fingerprints of sarcopenia and no single
established sarcopenia biomarker is specific for this condition.
Therefore, in this review we propose to focus on molecules that
spanning different systems and organs studying the link between
brain and muscle (Figure 1).
The core SNARE synaptosomal-associated protein of
25 kDa (SNAP25) could represent a promising pathway.
SNAP25 plays a central role in the release of neurotransmitters,
inhibiting the voltage-gated calcium channels (VGCC) function
and reducing responsiveness to depolarization. SNAP25
accumulates in the plasma membrane of nerve terminals at
NMJs, consistent with its SNARE protein role in regulating
exocytosis at peripheral and central synapses. In CNS, SNAP25
participates with syntaxin-1 and synaptobrevin/VAMP2 (53)
in the regulation of synaptic vesicle exocytosis. SNAP25
has two isoforms, SNAP25a and SNAP25b, resulting from
alternative splicing of the exon 5 of the SNAP25 gene,
which are differentially expressed during the development.
The reduction of this protein levels has been reported to
negatively affect synaptic function (54) and to be related
even to age-related diseases (i.e., Alzheimer’s disease and
diabetes) (55, 56). SNAP25 modulates VGCCs, it negatively
controls neuronal calcium responsiveness to depolarization
through VGCC inhibition (57). Consistently, silencing
endogenous SNAP25 in glutamatergic neurons results in
increased VGCC activity.
SNAP25 is synthesized in mouse motor nerve endings
and the level of SNAP25 mRNA affects neurotransmitter
exocytosis (58). Furthermore, neuromuscular transmission
FIGURE 1 | Muscle-specific and non-muscle-specific factors involved in sarcopenia.
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is compromised in the presence of a mutation in SNAP25b
gene that inhibits synaptic vesicle exocytosis (59). Notably,
adult SNAP25+/– mice express low protein levels and are
characterized by a decrease of neuromuscular strength (60),
suggesting that reduced levels of this protein negatively affect
neuromuscular function. These observations seem to be
supported by recent data showing that zebrafish embryos model
motor impairment, increased motility and neurotransmitter
secretion were associated with an over-expression of
SNAP25 (61).
CONCLUSIONS AND FUTURE
PERSPECTIVES
Even if sarcopenia and aging share common molecular and
cellular mechanisms, a definitive pathophysiological framework
of these conditions is still absent. There is, thus, the need of
employing a more comprehensive approach to study the age-
related changes of body composition leading to sarcopenia.
In particular, it is necessary to recognize the inadequacies of
previous paradigms, too often investigating sarcopenia as a
standalone disease, independently of the aging process.
Under this perspective it is necessary to deepen the study of
the brain-muscle link. NMJ seems to be the most innovative and
attractive marker of sarcopenia to study. This aspect represents
an important conceptual advance, because till now research
on sarcopenia has mainly focused on the study of muscular
factors and less on the possible role of neurological mechanisms
in its onset and development. Therefore, the SNARE complex
and, in particular SNAP25, may represent a promising pathway
to explore the molecular and cellular mechanisms regulating
muscular homeostasis and NMJs. In conclusion, the proposed
SNAP25 pathway could represent a new piece enriching the panel
of the established biomarkers of sarcopenia (Figure 1).
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